SlideShare a Scribd company logo
1 of 29
BME 4153-Independent project
Graphene oxide based fluorescence
resonance energy transfer biosensor
for breast cancer cells detection
HU RUIQI
11809482D
Supervisor: Dr. Mo Yang
April 2015
Outline
• Background
• Methodology
• Results & Discussion
• Conclusion
Background
• Cancer: the uncontrolled growth and spread of cells
(World Health Organization)
• Breast cancer: 3rd of top 10 cancers
(Hospital Authority, 2012)
• Severe threats & High mortality rate
• High significance and urgency for early diagnosis
Background
• The main cause of cancer deaths: metastasis
• leading cause of more than 90% of breast cancer
(Kanwar & Done, 2011)
• Circulating tumor cells (CTCs): main promoters of metastasis (Costa
et al., 2014)
• Released from the primary tumor into the bloodstream
• Detection of CTCs is actual purpose
• In this project: MCF-7 cells were used
Background
• Traditional method: Cancer screening tests
• Detect cancer before occurrence of symptoms
• Low accurate, low sensitive and not convenient
(Croswell et al., 2009)
• GO based biosensors were designed
• GO: nanomaterial
• Excellent optical and chemical properties
• High sensitivity and a significant part of biosensor
FRET phenomenon
• Fluorescence resonance energy transfer
• Photo excitation energy is transferred from a donor fluorophore to an accepter
molecule ( Morales-Narvaez and Merkoci, 2012)
• http://www.molecularbeacons.org/toto/Marras_energy_transfer.html
• Factors affecting on FRET:
• Distance
• Overlapping spectra
http://www.biomed.mtu.edu/StudentProjects/FRET.htm
In this project:
Donor: FAM/GQD
Acceptor: graphene oxide (GO)
Graphene oxide
• One-atom-thick nanostructure
• Has aromatic rings and binds with other molecules via π to π
stacking
• quenching capability
• In this project: GO acts as quencher
• http://www.graphenea.com/products/graphene-oxide
Aptamers
• Synthetic short sequences of DNA or RNA
• Bind to non-nucleic acid targets with high affinity and specificity
• More stable chemically and thermally
• A kind of Aptamer was selected: specifically recognize biomarker
on the MCF-7 cells and strongly bind with the cells
Objective
• To design and fabricate two types of GO based FRET biosensors
• FAM(fluorescent dye)-GO system
• GQD(fluorescent dye)-GO system
• To characterize the quenching efficiency of GO and the detection time of
detection for breast cancer cells
• To measure the sensitivity of the biosensor for breast cancer cells
Methodology
• Principle
• Procedures
Principle
Fluorescent dye:
FAM/GQD
Quencher: GO
Cells for detection: MC
7
Procedure:
• Step 1: Preparation
• FAM-aptamer was purchased from a company
• GQD-aptamer: conjugation of GQD with aptamers assisted by
EDC/NHS
• Step 2: Dilution
• Dilute GO into different concentrations
• Add GO & FAM/GQD-aptamer
into a container
Aptamer GQD GQD-Aptamer
Procedures
• Step 3: Obtaining FI & QE
• FAM-DNA: 465nm—520nm (Em:green)
• GQD-DNA: 360nm—465nm (Em:blue)
• Tecan Infinite F200 micro plate reader
• Step 4: Detection of MCF-7
• Add MCF-7 with different concentrations to determine detection limit
• http://www.news-medical.net/Infinite-200-PRO-NanoQuant-Microplate-Readers-from-Tecan
Signal Analysis
• Calculation of quenching efficiency
• F0’ =F0-background (PBS buffer)
• Fq’ =Fq-background
• QE (Quenching Efficiency) = (F0’-Fq’) / F0’
• Detection limit of MCF-7 were measured by plate reader
as well
Results
• FAM-GO FRET based essay
• GQD-GO FRET based essay
FAM-GO system
• Overlapping spectra between GO and FAM-aptamerFRET occur
FAM-DNA emission and GO absorption spectra
0
0.2
0.4
0.6
0.8
1
200 300 400 500 600 700 800
NormalizedFAMEm&GOAbs(a.u.)
Wavelength (nm)
FAM-ssDNA Em
GO Abs
FAM-GO system
• Obtained directly from FI reading of plate
reader (data extract after 30 mins)
• High concentration low fluorescent intensity
0
5000
10000
15000
20000
25000
30000
35000
40000
0 50 100 150 200
Fluorescentintensity(RFU)
GO Concentration ug/ml
Fluorescent intensity of FAM-ssDNA with
different concentration of GO
Calculate QE based on data
90% QE 100 µg/ml of GO
FAM-GO system
• High concentration of
GO high restoration of
FI of FAM
• Detection limit: 103 /ml
• 0 to a few thousand CTCs
per 1-10 ml blood sample
and other biosensor: LOD
can go down to 102/ml
(Flores et al., 2010; Talasaz et al., 2009)
• FAM: organic molecule
not stable & detection limit is not
enough
• GQD: fluorescence
nanoparticle
• More stable0
500
1000
1500
2000
2500
3000
3500
4000
0 3 6 9 12 15 18 21 24 27 30 33
Fluorescentintensity(RFU)
Time/t
Restortation of fluorescent signal of various
concentration of MCF-7
8.3*10^4/ml
6.7*10^4/ml
8.3*10^3/ml
FAM-GO system
Whole process for quenching and restoring fluorescent signal
• Detection time: Around 1 hour
• Slight shift to right after conjugation with aptamers
• But FI increase dramatically after emitting UV light
0
0.2
0.4
0.6
0.8
1
1.2
200 300 400 500 600 700 800
NormalizedGQDEm&GQD—
ssDNAEm(a.u.)
Wavelength (nm)
GQD Em
GQD-ssDNA Em
GQD-GO system
0
2000
4000
6000
8000
10000
12000
14000
Fluorescentintensity(RFU)
GQD GQD-DNA
Fluorescent intensity of GQD and GQD-DNA
GQD-ssDNA emission and GQD emission absorption spectra
(Inset: GQD at the top and GQD-ssDNA at the bottom)
FI difference before/after conjugation
GQD-GO system
• UV-vis: GQD: 360nm DNA: 260nm
• GQD-ssDNA: two peaks shown to make sure successful conjugation
Normalized absorbance intensity of GQD, GQD-ssDNA and orginal DNA
260nm
360nm
• Overlapping spectra between GO and GQD-aptamerFRET occur
GQD-DNA emission and GO absorption spectra
0
0.2
0.4
0.6
0.8
1
1.2
200 300 400 500 600 700 800
NormalizedGQDEm&GOAbs(a.u.)
Wavelength (nm)
GO Abs
GQD-ssDNA Em
GQD-GO system
GQD-GO system
• Obtained directly from fluorescent intensity
reading of plate reader (data extract after 10
mins)
• High concentration low fluorescent intensity
0
500
1000
1500
2000
2500
0 500 1000 1500 2000
FluorescentIntensity(RFU)
GO Concentration (µg/ml)
Fluorescent Intensity with different conc.
GO
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 200 400 600 800 1000 1200 1400 1600
QuenchingEfficiency
GO Concentration (µg/ml)
Quenching efficiency with different conc.GO
Calculate QE based on data
90% QE 800 µg/ml of GO
GQD-GO system
Whole process for quenching fluorescent signal
GQD-GO system
• Conc. GO: 800 µg/ml
• 20 µl MCF-7: different concentration
• High concentration no restoration of FI
0
100
200
300
400
500
600
700
800
900
1000
0 0.5 1 1.5 2 2.5 3 3.5
Fluorescentintensity(RFU)
Time (hour)
Restoration of Fluorescent intensity after adding MCF-7 with
different conc.
9.0×104 /ml
6.8 ×104/ml
4.5 ×104/ml
2.3 ×104/ml
Possible reason
• FAM-GO system:
• Only aptamers are π to π
stacking with GO
• Fluorescent dye-FAM not bind
with GO
• However,
• GQD-GO system:
• GQD bind with GO via π to π
stacking
• Both aptamers & GQD bind with
GO
•  much stronger binding than
aptamers with cells
• Solution:
Avoid binding between GQD and GO
Conclusion
• GO based FRET biosensors were designed
• FAM-GO FRET based essay:
• GO: 100 μg/ml to reach 90% QE
• Response time: 1 hour
• Detection of Limit: 103 /ml MCF-7
• GQD-GO FRET based essay:
• GO: 800 μg/ml to reach 90% QE
• Detection of MCF-7: not successful
• Reason: GQD can bind with GO via π to π stacking not only
aptamers
• Solution: passivation by PEG
Acknowledgement
• Special gratitude to supervisor: Dr. Mo Yang
• Appreciation on the research student SHI Jinyu
• Thanks for comment and advice from other supervisors
Thank You!
Q&A

More Related Content

What's hot

What is a Positron Emission Tomography?
What is a Positron Emission Tomography?What is a Positron Emission Tomography?
What is a Positron Emission Tomography?Yvonne Saura
 
proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...
proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...
proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...Amit Yadav
 
Metabolomics
MetabolomicsMetabolomics
Metabolomicspriya1111
 
2015 IEM CAC poster V1.0
2015 IEM CAC poster V1.02015 IEM CAC poster V1.0
2015 IEM CAC poster V1.0Qi Shao
 
20.pet scan in oncology
20.pet scan in oncology20.pet scan in oncology
20.pet scan in oncologyArnab Bose
 
1.proteomics coursework-3 dec2012-aky
1.proteomics coursework-3 dec2012-aky1.proteomics coursework-3 dec2012-aky
1.proteomics coursework-3 dec2012-akyAmit Yadav
 
Evgeny nikolaev proteomics of body liquids as a source for potential methods ...
Evgeny nikolaev proteomics of body liquids as a source for potential methods ...Evgeny nikolaev proteomics of body liquids as a source for potential methods ...
Evgeny nikolaev proteomics of body liquids as a source for potential methods ...igorod
 
molecular imaging with PET & SPECT
molecular imaging with PET & SPECTmolecular imaging with PET & SPECT
molecular imaging with PET & SPECTShatha M
 
Molecular Imaging
Molecular ImagingMolecular Imaging
Molecular Imaginggumccomm
 
Calcium influx assay and flow cytometry
Calcium influx assay and flow cytometry  Calcium influx assay and flow cytometry
Calcium influx assay and flow cytometry DHINESHKUMAR V
 
2.proteomics coursework 5-dec2012_aky
2.proteomics coursework 5-dec2012_aky2.proteomics coursework 5-dec2012_aky
2.proteomics coursework 5-dec2012_akyAmit Yadav
 
Anticancer drug discovery using multicellular tumor spheroid models
Anticancer drug discovery using multicellular tumor spheroid modelsAnticancer drug discovery using multicellular tumor spheroid models
Anticancer drug discovery using multicellular tumor spheroid modelsHasnat Tariq
 

What's hot (20)

What is a Positron Emission Tomography?
What is a Positron Emission Tomography?What is a Positron Emission Tomography?
What is a Positron Emission Tomography?
 
proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...
proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...
proteomics, mass spectrometry, science, bioinformatics, electrophoresis, liqu...
 
Molecular imaging and therapy in prostate cancer
Molecular imaging and therapy in prostate cancerMolecular imaging and therapy in prostate cancer
Molecular imaging and therapy in prostate cancer
 
Metabolomics
MetabolomicsMetabolomics
Metabolomics
 
2015 IEM CAC poster V1.0
2015 IEM CAC poster V1.02015 IEM CAC poster V1.0
2015 IEM CAC poster V1.0
 
20.pet scan in oncology
20.pet scan in oncology20.pet scan in oncology
20.pet scan in oncology
 
1.proteomics coursework-3 dec2012-aky
1.proteomics coursework-3 dec2012-aky1.proteomics coursework-3 dec2012-aky
1.proteomics coursework-3 dec2012-aky
 
proteomics
 proteomics proteomics
proteomics
 
Evgeny nikolaev proteomics of body liquids as a source for potential methods ...
Evgeny nikolaev proteomics of body liquids as a source for potential methods ...Evgeny nikolaev proteomics of body liquids as a source for potential methods ...
Evgeny nikolaev proteomics of body liquids as a source for potential methods ...
 
molecular imaging with PET & SPECT
molecular imaging with PET & SPECTmolecular imaging with PET & SPECT
molecular imaging with PET & SPECT
 
Poster
PosterPoster
Poster
 
Molecular Imaging
Molecular ImagingMolecular Imaging
Molecular Imaging
 
Calcium influx assay and flow cytometry
Calcium influx assay and flow cytometry  Calcium influx assay and flow cytometry
Calcium influx assay and flow cytometry
 
2.proteomics coursework 5-dec2012_aky
2.proteomics coursework 5-dec2012_aky2.proteomics coursework 5-dec2012_aky
2.proteomics coursework 5-dec2012_aky
 
Anticancer drug discovery using multicellular tumor spheroid models
Anticancer drug discovery using multicellular tumor spheroid modelsAnticancer drug discovery using multicellular tumor spheroid models
Anticancer drug discovery using multicellular tumor spheroid models
 
PET-CT in Oncology
PET-CT in OncologyPET-CT in Oncology
PET-CT in Oncology
 
Proteomics
ProteomicsProteomics
Proteomics
 
Proteomics
ProteomicsProteomics
Proteomics
 
Biotech2012 spring 3_metabolomics
Biotech2012 spring 3_metabolomicsBiotech2012 spring 3_metabolomics
Biotech2012 spring 3_metabolomics
 
Proteomics
ProteomicsProteomics
Proteomics
 

Viewers also liked

Biosensor for Early Detection of Breast Cancer - LIKA-CESAR Partnership
Biosensor for Early Detection of Breast Cancer - LIKA-CESAR PartnershipBiosensor for Early Detection of Breast Cancer - LIKA-CESAR Partnership
Biosensor for Early Detection of Breast Cancer - LIKA-CESAR PartnershipCESAR
 
Nanobiosensors
NanobiosensorsNanobiosensors
Nanobiosensorstabirsir
 
Uses of biosensors
Uses of biosensorsUses of biosensors
Uses of biosensorsLeeya Najwa
 
Breast Cancer Awareness Presentation
Breast Cancer Awareness Presentation Breast Cancer Awareness Presentation
Breast Cancer Awareness Presentation RacDokki
 

Viewers also liked (11)

salivaomics by Dr.Ilakkiya Balasubramaniyan
salivaomics by Dr.Ilakkiya Balasubramaniyansalivaomics by Dr.Ilakkiya Balasubramaniyan
salivaomics by Dr.Ilakkiya Balasubramaniyan
 
Biosensor for Early Detection of Breast Cancer - LIKA-CESAR Partnership
Biosensor for Early Detection of Breast Cancer - LIKA-CESAR PartnershipBiosensor for Early Detection of Breast Cancer - LIKA-CESAR Partnership
Biosensor for Early Detection of Breast Cancer - LIKA-CESAR Partnership
 
Nanobiosensors
NanobiosensorsNanobiosensors
Nanobiosensors
 
Biosensor
BiosensorBiosensor
Biosensor
 
Uses of biosensors
Uses of biosensorsUses of biosensors
Uses of biosensors
 
Nanobiosensors
NanobiosensorsNanobiosensors
Nanobiosensors
 
Biosensor
BiosensorBiosensor
Biosensor
 
Biosensor ppt
Biosensor pptBiosensor ppt
Biosensor ppt
 
Biosensors
BiosensorsBiosensors
Biosensors
 
Biosensors
BiosensorsBiosensors
Biosensors
 
Breast Cancer Awareness Presentation
Breast Cancer Awareness Presentation Breast Cancer Awareness Presentation
Breast Cancer Awareness Presentation
 

Similar to attachment3654CA09

High Throughput Screening for ARV Drugs in HIV Prevention Studies
High Throughput Screening for ARV Drugs in HIV Prevention StudiesHigh Throughput Screening for ARV Drugs in HIV Prevention Studies
High Throughput Screening for ARV Drugs in HIV Prevention StudiesHopkinsCFAR
 
Target capture of DNA from FFPE samples— recommendations for generating robus...
Target capture of DNA from FFPE samples— recommendations for generating robus...Target capture of DNA from FFPE samples— recommendations for generating robus...
Target capture of DNA from FFPE samples— recommendations for generating robus...Integrated DNA Technologies
 
Lecture 2 diagnostic molecular microbiology bls
Lecture 2 diagnostic molecular microbiology blsLecture 2 diagnostic molecular microbiology bls
Lecture 2 diagnostic molecular microbiology blsBruno Mmassy
 
IMarEST Compliance Testing Presentation. Evaluation of onboard methods
IMarEST Compliance Testing Presentation. Evaluation of onboard methodsIMarEST Compliance Testing Presentation. Evaluation of onboard methods
IMarEST Compliance Testing Presentation. Evaluation of onboard methodsStephanie Lavelle
 
2013-09-03 Radboudumc NCMLS Technical Forum
2013-09-03 Radboudumc NCMLS Technical Forum2013-09-03 Radboudumc NCMLS Technical Forum
2013-09-03 Radboudumc NCMLS Technical ForumAlain van Gool
 
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesOligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesPine Lake Laboratories
 
Cytation 5 single sheet english version
Cytation 5 single sheet   english versionCytation 5 single sheet   english version
Cytation 5 single sheet english versionMaziar Yari
 
Cytation 5 single sheet english version
Cytation 5 single sheet   english versionCytation 5 single sheet   english version
Cytation 5 single sheet english versionMaziar Yari
 
Practical Issues of FISH in Solid Tumors
Practical Issues of FISH in Solid TumorsPractical Issues of FISH in Solid Tumors
Practical Issues of FISH in Solid TumorsYosep Chong
 
Newer Diagnostic Modality in Tuberculosis.pptx
Newer Diagnostic Modality in Tuberculosis.pptxNewer Diagnostic Modality in Tuberculosis.pptx
Newer Diagnostic Modality in Tuberculosis.pptxBIMALESHYADAV2
 
Employing ForteBio Octet platform for the development of a dual-binding poten...
Employing ForteBio Octet platform for the development of a dual-binding poten...Employing ForteBio Octet platform for the development of a dual-binding poten...
Employing ForteBio Octet platform for the development of a dual-binding poten...KBI Biopharma
 
Quanterix Long Sales Presentation_SK
Quanterix Long Sales Presentation_SKQuanterix Long Sales Presentation_SK
Quanterix Long Sales Presentation_SKSteve Klose
 
Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...
Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...
Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...AliElmehdawi2
 
"Productivity and Simplicity" - Streamlining Cumbersome Sample Preparation i...
"Productivity and Simplicity" -  Streamlining Cumbersome Sample Preparation i..."Productivity and Simplicity" -  Streamlining Cumbersome Sample Preparation i...
"Productivity and Simplicity" - Streamlining Cumbersome Sample Preparation i...Oscar Cabrices PhD
 
Maldi tof-ms analysis in identification of prostate cancer
Maldi tof-ms analysis in identification of prostate cancerMaldi tof-ms analysis in identification of prostate cancer
Maldi tof-ms analysis in identification of prostate cancerMoustafa Rezk
 
Platform Techniques for Preformulation Development for Non-Antibody Products
Platform Techniques for Preformulation Development for Non-Antibody ProductsPlatform Techniques for Preformulation Development for Non-Antibody Products
Platform Techniques for Preformulation Development for Non-Antibody ProductsKBI Biopharma
 
Comparison of Formulation Analysis by UPLC FINAL
Comparison of Formulation Analysis by UPLC FINALComparison of Formulation Analysis by UPLC FINAL
Comparison of Formulation Analysis by UPLC FINALJessica Sitko
 

Similar to attachment3654CA09 (20)

High Throughput Screening for ARV Drugs in HIV Prevention Studies
High Throughput Screening for ARV Drugs in HIV Prevention StudiesHigh Throughput Screening for ARV Drugs in HIV Prevention Studies
High Throughput Screening for ARV Drugs in HIV Prevention Studies
 
Target capture of DNA from FFPE samples— recommendations for generating robus...
Target capture of DNA from FFPE samples— recommendations for generating robus...Target capture of DNA from FFPE samples— recommendations for generating robus...
Target capture of DNA from FFPE samples— recommendations for generating robus...
 
Lecture 2 diagnostic molecular microbiology bls
Lecture 2 diagnostic molecular microbiology blsLecture 2 diagnostic molecular microbiology bls
Lecture 2 diagnostic molecular microbiology bls
 
IMarEST Compliance Testing Presentation. Evaluation of onboard methods
IMarEST Compliance Testing Presentation. Evaluation of onboard methodsIMarEST Compliance Testing Presentation. Evaluation of onboard methods
IMarEST Compliance Testing Presentation. Evaluation of onboard methods
 
2013-09-03 Radboudumc NCMLS Technical Forum
2013-09-03 Radboudumc NCMLS Technical Forum2013-09-03 Radboudumc NCMLS Technical Forum
2013-09-03 Radboudumc NCMLS Technical Forum
 
qtofmultiresidues2
qtofmultiresidues2qtofmultiresidues2
qtofmultiresidues2
 
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesOligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake Laboratories
 
Cytation 5 single sheet english version
Cytation 5 single sheet   english versionCytation 5 single sheet   english version
Cytation 5 single sheet english version
 
Cytation 5 single sheet english version
Cytation 5 single sheet   english versionCytation 5 single sheet   english version
Cytation 5 single sheet english version
 
Practical Issues of FISH in Solid Tumors
Practical Issues of FISH in Solid TumorsPractical Issues of FISH in Solid Tumors
Practical Issues of FISH in Solid Tumors
 
Newer Diagnostic Modality in Tuberculosis.pptx
Newer Diagnostic Modality in Tuberculosis.pptxNewer Diagnostic Modality in Tuberculosis.pptx
Newer Diagnostic Modality in Tuberculosis.pptx
 
Employing ForteBio Octet platform for the development of a dual-binding poten...
Employing ForteBio Octet platform for the development of a dual-binding poten...Employing ForteBio Octet platform for the development of a dual-binding poten...
Employing ForteBio Octet platform for the development of a dual-binding poten...
 
Quanterix Long Sales Presentation_SK
Quanterix Long Sales Presentation_SKQuanterix Long Sales Presentation_SK
Quanterix Long Sales Presentation_SK
 
Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...
Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...
Seth Rodgers - High Throughput Cell Culture Platform for Bioprocess Optimizat...
 
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
 
"Productivity and Simplicity" - Streamlining Cumbersome Sample Preparation i...
"Productivity and Simplicity" -  Streamlining Cumbersome Sample Preparation i..."Productivity and Simplicity" -  Streamlining Cumbersome Sample Preparation i...
"Productivity and Simplicity" - Streamlining Cumbersome Sample Preparation i...
 
Chromatography: Pesticide Residue Analysis Webinar Series: Part 3 of 4: Maxi...
Chromatography: Pesticide Residue Analysis Webinar Series:  Part 3 of 4: Maxi...Chromatography: Pesticide Residue Analysis Webinar Series:  Part 3 of 4: Maxi...
Chromatography: Pesticide Residue Analysis Webinar Series: Part 3 of 4: Maxi...
 
Maldi tof-ms analysis in identification of prostate cancer
Maldi tof-ms analysis in identification of prostate cancerMaldi tof-ms analysis in identification of prostate cancer
Maldi tof-ms analysis in identification of prostate cancer
 
Platform Techniques for Preformulation Development for Non-Antibody Products
Platform Techniques for Preformulation Development for Non-Antibody ProductsPlatform Techniques for Preformulation Development for Non-Antibody Products
Platform Techniques for Preformulation Development for Non-Antibody Products
 
Comparison of Formulation Analysis by UPLC FINAL
Comparison of Formulation Analysis by UPLC FINALComparison of Formulation Analysis by UPLC FINAL
Comparison of Formulation Analysis by UPLC FINAL
 

attachment3654CA09

  • 1. BME 4153-Independent project Graphene oxide based fluorescence resonance energy transfer biosensor for breast cancer cells detection HU RUIQI 11809482D Supervisor: Dr. Mo Yang April 2015
  • 2. Outline • Background • Methodology • Results & Discussion • Conclusion
  • 3. Background • Cancer: the uncontrolled growth and spread of cells (World Health Organization) • Breast cancer: 3rd of top 10 cancers (Hospital Authority, 2012) • Severe threats & High mortality rate • High significance and urgency for early diagnosis
  • 4. Background • The main cause of cancer deaths: metastasis • leading cause of more than 90% of breast cancer (Kanwar & Done, 2011) • Circulating tumor cells (CTCs): main promoters of metastasis (Costa et al., 2014) • Released from the primary tumor into the bloodstream • Detection of CTCs is actual purpose • In this project: MCF-7 cells were used
  • 5. Background • Traditional method: Cancer screening tests • Detect cancer before occurrence of symptoms • Low accurate, low sensitive and not convenient (Croswell et al., 2009) • GO based biosensors were designed • GO: nanomaterial • Excellent optical and chemical properties • High sensitivity and a significant part of biosensor
  • 6. FRET phenomenon • Fluorescence resonance energy transfer • Photo excitation energy is transferred from a donor fluorophore to an accepter molecule ( Morales-Narvaez and Merkoci, 2012) • http://www.molecularbeacons.org/toto/Marras_energy_transfer.html • Factors affecting on FRET: • Distance • Overlapping spectra http://www.biomed.mtu.edu/StudentProjects/FRET.htm In this project: Donor: FAM/GQD Acceptor: graphene oxide (GO)
  • 7. Graphene oxide • One-atom-thick nanostructure • Has aromatic rings and binds with other molecules via π to π stacking • quenching capability • In this project: GO acts as quencher • http://www.graphenea.com/products/graphene-oxide
  • 8. Aptamers • Synthetic short sequences of DNA or RNA • Bind to non-nucleic acid targets with high affinity and specificity • More stable chemically and thermally • A kind of Aptamer was selected: specifically recognize biomarker on the MCF-7 cells and strongly bind with the cells
  • 9. Objective • To design and fabricate two types of GO based FRET biosensors • FAM(fluorescent dye)-GO system • GQD(fluorescent dye)-GO system • To characterize the quenching efficiency of GO and the detection time of detection for breast cancer cells • To measure the sensitivity of the biosensor for breast cancer cells
  • 12. Procedure: • Step 1: Preparation • FAM-aptamer was purchased from a company • GQD-aptamer: conjugation of GQD with aptamers assisted by EDC/NHS • Step 2: Dilution • Dilute GO into different concentrations • Add GO & FAM/GQD-aptamer into a container Aptamer GQD GQD-Aptamer
  • 13. Procedures • Step 3: Obtaining FI & QE • FAM-DNA: 465nm—520nm (Em:green) • GQD-DNA: 360nm—465nm (Em:blue) • Tecan Infinite F200 micro plate reader • Step 4: Detection of MCF-7 • Add MCF-7 with different concentrations to determine detection limit • http://www.news-medical.net/Infinite-200-PRO-NanoQuant-Microplate-Readers-from-Tecan
  • 14. Signal Analysis • Calculation of quenching efficiency • F0’ =F0-background (PBS buffer) • Fq’ =Fq-background • QE (Quenching Efficiency) = (F0’-Fq’) / F0’ • Detection limit of MCF-7 were measured by plate reader as well
  • 15. Results • FAM-GO FRET based essay • GQD-GO FRET based essay
  • 16. FAM-GO system • Overlapping spectra between GO and FAM-aptamerFRET occur FAM-DNA emission and GO absorption spectra 0 0.2 0.4 0.6 0.8 1 200 300 400 500 600 700 800 NormalizedFAMEm&GOAbs(a.u.) Wavelength (nm) FAM-ssDNA Em GO Abs
  • 17. FAM-GO system • Obtained directly from FI reading of plate reader (data extract after 30 mins) • High concentration low fluorescent intensity 0 5000 10000 15000 20000 25000 30000 35000 40000 0 50 100 150 200 Fluorescentintensity(RFU) GO Concentration ug/ml Fluorescent intensity of FAM-ssDNA with different concentration of GO Calculate QE based on data 90% QE 100 µg/ml of GO
  • 18. FAM-GO system • High concentration of GO high restoration of FI of FAM • Detection limit: 103 /ml • 0 to a few thousand CTCs per 1-10 ml blood sample and other biosensor: LOD can go down to 102/ml (Flores et al., 2010; Talasaz et al., 2009) • FAM: organic molecule not stable & detection limit is not enough • GQD: fluorescence nanoparticle • More stable0 500 1000 1500 2000 2500 3000 3500 4000 0 3 6 9 12 15 18 21 24 27 30 33 Fluorescentintensity(RFU) Time/t Restortation of fluorescent signal of various concentration of MCF-7 8.3*10^4/ml 6.7*10^4/ml 8.3*10^3/ml
  • 19. FAM-GO system Whole process for quenching and restoring fluorescent signal • Detection time: Around 1 hour
  • 20. • Slight shift to right after conjugation with aptamers • But FI increase dramatically after emitting UV light 0 0.2 0.4 0.6 0.8 1 1.2 200 300 400 500 600 700 800 NormalizedGQDEm&GQD— ssDNAEm(a.u.) Wavelength (nm) GQD Em GQD-ssDNA Em GQD-GO system 0 2000 4000 6000 8000 10000 12000 14000 Fluorescentintensity(RFU) GQD GQD-DNA Fluorescent intensity of GQD and GQD-DNA GQD-ssDNA emission and GQD emission absorption spectra (Inset: GQD at the top and GQD-ssDNA at the bottom) FI difference before/after conjugation
  • 21. GQD-GO system • UV-vis: GQD: 360nm DNA: 260nm • GQD-ssDNA: two peaks shown to make sure successful conjugation Normalized absorbance intensity of GQD, GQD-ssDNA and orginal DNA 260nm 360nm
  • 22. • Overlapping spectra between GO and GQD-aptamerFRET occur GQD-DNA emission and GO absorption spectra 0 0.2 0.4 0.6 0.8 1 1.2 200 300 400 500 600 700 800 NormalizedGQDEm&GOAbs(a.u.) Wavelength (nm) GO Abs GQD-ssDNA Em GQD-GO system
  • 23. GQD-GO system • Obtained directly from fluorescent intensity reading of plate reader (data extract after 10 mins) • High concentration low fluorescent intensity 0 500 1000 1500 2000 2500 0 500 1000 1500 2000 FluorescentIntensity(RFU) GO Concentration (µg/ml) Fluorescent Intensity with different conc. GO 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 0 200 400 600 800 1000 1200 1400 1600 QuenchingEfficiency GO Concentration (µg/ml) Quenching efficiency with different conc.GO Calculate QE based on data 90% QE 800 µg/ml of GO
  • 24. GQD-GO system Whole process for quenching fluorescent signal
  • 25. GQD-GO system • Conc. GO: 800 µg/ml • 20 µl MCF-7: different concentration • High concentration no restoration of FI 0 100 200 300 400 500 600 700 800 900 1000 0 0.5 1 1.5 2 2.5 3 3.5 Fluorescentintensity(RFU) Time (hour) Restoration of Fluorescent intensity after adding MCF-7 with different conc. 9.0×104 /ml 6.8 ×104/ml 4.5 ×104/ml 2.3 ×104/ml
  • 26. Possible reason • FAM-GO system: • Only aptamers are π to π stacking with GO • Fluorescent dye-FAM not bind with GO • However, • GQD-GO system: • GQD bind with GO via π to π stacking • Both aptamers & GQD bind with GO •  much stronger binding than aptamers with cells • Solution: Avoid binding between GQD and GO
  • 27. Conclusion • GO based FRET biosensors were designed • FAM-GO FRET based essay: • GO: 100 μg/ml to reach 90% QE • Response time: 1 hour • Detection of Limit: 103 /ml MCF-7 • GQD-GO FRET based essay: • GO: 800 μg/ml to reach 90% QE • Detection of MCF-7: not successful • Reason: GQD can bind with GO via π to π stacking not only aptamers • Solution: passivation by PEG
  • 28. Acknowledgement • Special gratitude to supervisor: Dr. Mo Yang • Appreciation on the research student SHI Jinyu • Thanks for comment and advice from other supervisors